Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EEV-001
- Development stage
- Preclinical
- Lead developer
- INOVIQ
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cell Therapies
01
Overview
EEV-001 is a preclinical-stage therapeutic candidate being developed by INOVIQ for the treatment of breast cancer. It utilizes a CAR-exosome (Chimeric Antigen Receptor-engineered exosome) platform, which involves modifying extracellular vesicles (EVs) to express specific receptors on their surface. This approach is designed to combine the targeting precision of CAR technology with the natural delivery advantages of exosomes, potentially allowing for the specific direction of therapeutic payloads or exosomal activity to tumor cells while minimizing off-target effects. EEV-001 is currently identified as a priority in INOVIQ's research and development pipeline.
Beyond the preview
Go deeper on EEV-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EEV-001.